BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/23/2020 10:54:17 AM | Browse: 687 | Download: 1286
 |
Received |
|
2020-05-18 17:46 |
|
Peer-Review Started |
|
2020-05-18 17:47 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-06-03 17:30 |
|
Revised |
|
2020-06-09 10:43 |
|
Second Decision |
|
2020-09-22 11:02 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-09-22 20:23 |
|
Articles in Press |
|
2020-09-22 20:23 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-10-10 06:31 |
|
Typeset the Manuscript |
|
2020-11-08 05:43 |
|
Publish the Manuscript Online |
|
2020-11-23 10:54 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Opinion Review |
| Article Title |
Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Federico Piñero, Marcos Thompson, Juan Ignacio Marín and Marcelo Silva |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Federico Piñero, MD, MSc, Academic Research, Doctor, Doctor, Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Av. Presidente Perón 1500, Pilar, Buenos Aires B1629HJ, Argentina. fpinerof@cas.austral.edu.ar |
| Key Words |
Liver transplantation; Recurrence; Systemic therapies; Hepatocellular carcinoma; ; |
| Core Tip |
Post-transplant hepatocellular carcinoma recurrence is a significant negative predictor of survival. There is no consensus in the treatment of recurrence. If possible, resection should be attempted. The use of systemic chemotherapy after transplant is limited to small retrospective cohort studies. Immunotherapy with checkpoint inhibitors in the post-transplant setting is challenging due to the potentially increased risk of allograft rejection. This opinion review illustrates a late post-transplant hepatocellular carcinoma recurrence treated with lenvatinib, with good tolerance and overall survival after lung and adrenal metastasis resections in a patient previously intolerant to sorafenib. |
| Publish Date |
2020-11-23 10:54 |
| Citation |
Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020; 10(11): 297-306 |
| URL |
https://www.wjgnet.com/2220-3230/full/v10/i11/297.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v10.i11.297 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
